This infographic from the Tropeninstitut illustrates the malaria transmission cycle. It begins when an Anopheles mosquito bites a human and injects its sporozoites into the bloodstream. The sporozoites then travel to the liver where they mature and release merozoites back into the bloodstream. The m...erozoites then infect red blood cells, resulting in the clinical symptoms of malaria. Some merozoites develop into gametocytes, which can be ingested by another mosquito when it bites the infected person again, thus continuing the transmission cycle.
The infographic serves as an educational tool, helping to explain the complex life cycle of the malaria parasite and the role of mosquitoes in spreading the disease.
Accessed on 26/08/2025.
more
Antimalarial chemotherapy is crucial for reducing morbidity, mortality, and drug resistance, and is the cornerstone of malaria control. Existing antimalarial drugs act at different stages of the parasite’s life cycle. These drugs range from classic agents such as chloroquine and quinine to newer a...rtemisinin derivatives. They include tissue schizonticides, blood schizonticides, gametocytocides, and sporontocides. Artemisinin and its derivatives are the most effective and fastest-acting treatment against drug-resistant Plasmodium falciparum, achieving rapid parasite clearance and reducing transmission potential. Other key drugs include mefloquine, halofantrine, proguanil, sulfadoxine–pyrimethamine, atovaquone–proguanil, tetracyclines, clindamycin and azithromycin. Each of these drugs has a specific mechanism of action, pharmacokinetics, efficacy, safety profile and contraindications. Rational drug combinations and adherence to national treatment guidelines are essential for managing resistance, ensuring safety in vulnerable populations such as children and pregnant women, and optimising therapeutic outcomes in cases of both uncomplicated and severe malaria.
more
A pesar de los avances, persisten importantes barreras para el diagnóstico y tratamiento oportunos de la malaria en las Américas, especialmente en zonas rurales y de difícil acceso. Para reducir la transmisión, es esencial ampliar el uso de pruebas de diagnóstico rápido y garantizar la disponi...bilidad gratuita de antimaláricos como bienes públicos. La OPS propone un marco estratégico para eliminar obstáculos, acelerar el inicio del tratamiento y contribuir a la eliminación de la enfermedad en la región.
more
This website provides comprehensive guidance on vaccinations, malaria prevention and general health measures for travellers to tropical and developing regions. It emphasises two main vaccination criteria: the administrative requirements of the destination country and the actual health risks to the t...raveller. Malaria prevention measures include chemoprophylaxis (e.g. atovaquone-proguanil, doxycycline or mefloquine) and vector control methods such as insecticide-treated nets, insect repellents and environmental protection measures. Additional travel health risks covered include bites from other arthropods, envenomations, dog and mammal bites, food and water hygiene, traveller's diarrhoea, and considerations for pregnant women, infants, the elderly, and people with chronic conditions. It strongly recommends carrying a travel medical kit and having a pre-travel consultation. Overall, the document aims to minimise illness and ensure safe travel.
Accessed on 27/08/2025.
more
Combination therapy is a cornerstone of modern malaria treatment, particularly in the context of widespread multidrug resistance. Using two or more antimalarial drugs with different mechanisms simultaneously enhances efficacy, shortens treatment duration, improves compliance and delays the developme...nt of resistance. Artemisinin-based combination therapies (ACTs), such as artemether–lumefantrine, artesunate–amodiaquine and artesunate–sulfadoxine/pyrimethamine, are highly effective in rapidly clearing parasites and reducing gametocyte carriage. They are also generally well tolerated. Non-artemisinin combinations, quinine-based regimens and novel combinations (e.g. piperaquine–dihydroartemisinin) offer alternative therapeutic options, although clinical experience with these remains limited. Although ACTs are the preferred first-line treatment, factors such as cost, local drug resistance patterns, safety during pregnancy and paediatric use must inform implementation and policy decisions.
more